Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine

References

• Stephens DS. Conquering the meningococcus. FEMS Microbiol. Rev.31(1), 3–14 (2007).
   PubMed Web of Science ®Google Scholar
• Boisier P, Nicolas P, Djibo S et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin. Infect. Dis.44(5), 657–663 (2007).
   PubMed Web of Science ®Google Scholar
• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet369(9580), 2196–2210 (2007).
   PubMed Web of Science ®Google Scholar
• Wyle FA, Artenstein MS, Brandt BL et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis.126(5), 514–521 (1972).
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet2(8346), 355–357 (1983).
   PubMed Web of Science ®Google Scholar
• Boslego J, Garcia J, Cruz C et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine13(9), 821–829 (1995).
   PubMed Web of Science ®Google Scholar
• Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14(2), 195–207; discussion 208–110 (1991).
   PubMedGoogle Scholar
• de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet340(8827), 1074–1078 (1992).
   PubMed Web of Science ®Google Scholar
• Bjune G, Hoiby EA, Gronnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338(8775), 1093–1096 (1991).
   PubMed Web of Science ®Google Scholar
• O’Hallahan J, McNicholas A, Galloway Y, O’Leary E, Roseveare C. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. NZ Med. J.122(1291), 48–59 (2009).
   PubMedGoogle Scholar
• Kelly C, Arnold R, Galloway Y, O’Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am. J. Epidemiol.166(7), 817–823 (2007).
   PubMed Web of Science ®Google Scholar
• Galloway Y, Stehr-Green P, McNicholas A, O’Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epidemiol.38(2), 413–418 (2009).
   PubMed Web of Science ®Google Scholar
• Wong S, Lennon D, Jackson C et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16–24 months. Pediatr. Infect. Dis. J.26(4), 345–350 (2007).
   PubMed Web of Science ®Google Scholar
• Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281(16), 1520–1527 (1999).
   PubMed Web of Science ®Google Scholar
• Feiring B, Fuglesang J, Oster P et al. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin. Vaccine Immunol.13(7), 790–796 (2006).
   Google Scholar
• Wedege E, Bolstad K, Aase A et al. Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin. Vaccine Immunol.14(7), 830–838 (2007).
   PubMedGoogle Scholar
• Rappuoli R. Reverse vaccinology. Curr. Opin. Microbiol.3(5), 445–450 (2000).
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA103(29), 10834–10839 (2006).
   PubMed Web of Science ®Google Scholar
• Miller E, Pollard AJ, Borrow R et al. Safety and immunogenicity of Novartis meningococcal serogroup B vaccine after three doses administered in infancy. Presented at: 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Graz, Austria, 13–17 May 2008.
   Google Scholar
• Fletcher LD, Bernfield L, Barniak V et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun.72(4), 2088–2100 (2004).
   PubMed Web of Science ®Google Scholar
• Nissen M, Marshall H, Richmond P, Lambert S, Roberton D, Gruber W. A randomized, placebo-controlled, double-blind, Phase 1 trial of ascending doses of meningococcal group B rLP2086 vaccine. Presented at: 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Graz, Austria, 13–17 May 2008.
   Google Scholar
• Maiden MC, Bygraves JA, Feil E et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc. Natl Acad. Sci. USA95(6), 3140–3145 (1998).
   PubMed Web of Science ®Google Scholar
• Urwin R, Maiden MC. Multi-locus sequence typing: a tool for global epidemiology. Trends Microbiol.11(10), 479–487 (2003).
   PubMed Web of Science ®Google Scholar
• Bygraves JA, Urwin R, Fox AJ et al. Population genetic and evolutionary approaches to analysis of Neisseria meningitidis isolates belonging to the ET-5 complex. J. Bacteriol.181(18), 5551–5556 (1999).
   Google Scholar
• Caugant DA. Genetics and evolution of Neisseria meningitidis: importance for the epidemiology of meningococcal disease. Infect. Genet. Evol.8(5), 558–565 (2008).
   PubMed Web of Science ®Google Scholar
• Buckee CO, Jolley KA, Recker M et al. Role of selection in the emergence of lineages and the evolution of virulence in Neisseria meningitidis. Proc. Natl Acad. Sci. USA105(39), 15082–15087 (2008).
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Comanducci M, Findlow J et al. Characterization of fHbp, NHBA (GNA2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J. Clin. Microbiol.47(11), 3577–3585 (2009).
   PubMed Web of Science ®Google Scholar
• Jolley KA, Brehony C, Maiden MC. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol. Rev.31(1), 89–96 (2007).
   PubMed Web of Science ®Google Scholar
• Caugant DA, Maiden MC. Meningococcal carriage and disease – population biology and evolution. Vaccine27(Suppl. 2), B64–B70 (2009).
   PubMed Web of Science ®Google Scholar
• Schoen C, Blom J, Claus H et al. Whole-genome comparison of disease and carriage strains provides insights into virulence evolution in Neisseria meningitidis. Proc. Natl Acad. Sci. USA105(9), 3473–3478 (2008).
   PubMed Web of Science ®Google Scholar
• Yazdankhah SP, Lindstedt BA, Caugant DA. Use of variable-number tandem repeats to examine genetic diversity of Neisseria meningitidis. J. Clin. Microbiol.43(4), 1699–1705 (2005).
   PubMed Web of Science ®Google Scholar
• Tettelin H, Saunders NJ, Heidelberg J et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science287(5459), 1809–1815 (2000).
   PubMed Web of Science ®Google Scholar
• Ambur OH, Frye SA, Tonjum T. New functional identity for the DNA uptake sequence in transformation and its presence in transcriptional terminators. J. Bacteriol.189(5), 2077–2085 (2007).
   PubMed Web of Science ®Google Scholar
• Hanage WP, Fraser C, Spratt BG. The impact of homologous recombination on the generation of diversity in bacteria. J. Theor. Biol.239(2), 210–219 (2006).
   PubMed Web of Science ®Google Scholar
• Saunders NJ, Jeffries AC, Peden JF et al. Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58. Mol. Microbiol.37(1), 207–215 (2000).
   PubMed Web of Science ®Google Scholar
• Bowler LD, Zhang QY, Riou JY, Spratt BG. Interspecies recombination between the penA genes of Neisseria meningitidis and commensal Neisseria species during the emergence of penicillin resistance in N. meningitidis: natural events and laboratory simulation. J. Bacteriol.176(2), 333–337 (1994).
   PubMed Web of Science ®Google Scholar
• Feil EJ, Maiden MC, Achtman M, Spratt BG. The relative contributions of recombination and mutation to the divergence of clones of Neisseria meningitidis. Mol. Biol. Evol.16(11), 1496–1502 (1999).
   PubMedGoogle Scholar
• Lavezzo E, Toppo S, Barzon L et al. Draft genome sequences of two Neisseria meningitidis serogroup C clinical isolates. J. Bacteriol. DOI: 10.1128/JB.00789–00710 (2010) (Epub ahead of print).
   Google Scholar
• Harrison LH, Jolley KA, Shutt KA et al. Antigenic shift and increased incidence of meningococcal disease. J. Infect. Dis.193(9), 1266–1274 (2006).
   PubMed Web of Science ®Google Scholar
• Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin. Microbiol. Rev.19(1), 142–164 (2006).
   PubMed Web of Science ®Google Scholar
• Swartley JS, Marfin AA, Edupuganti S et al. Capsule switching of Neisseria meningitidis. Proc. Natl Acad. Sci. USA94(1), 271–276 (1997).
   PubMed Web of Science ®Google Scholar
• Kriz P, Kriz B, Svandova E, Musilek M. Antimeningococcal herd immunity in the Czech Republic – influence of an emerging clone, Neisseria meningitidis ET-15/37. Epidemiol. Infect.123(2), 193–200 (1999).
   PubMed Web of Science ®Google Scholar
• Marri PR, Paniscus M, Weyand NJ et al. Genome sequencing reveals widespread virulence gene exchange among human Neisseria species. PLoS One5(7), e11835 (2010).
   PubMed Web of Science ®Google Scholar
• De Gregorio E, Abrescia C, Carlomagno MS, Di Nocera PP. Asymmetrical distribution of Neisseria miniature insertion sequence DNA repeats among pathogenic and nonpathogenic Neisseria strains. Infect. Immun.71(7), 4217–4221 (2003).
   Google Scholar
• Liu SV, Saunders NJ, Jeffries A, Rest RF. Genome analysis and strain comparison of correia repeats and correia repeat-enclosed elements in pathogenic Neisseria. J. Bacteriol.184(22), 6163–6173 (2002).
   PubMed Web of Science ®Google Scholar
• Rouquette-Loughlin CE, Balthazar JT, Hill SA, Shafer WM. Modulation of the mtrCDE-encoded efflux pump gene complex of Neisseria meningitidis due to a Correia element insertion sequence. Mol. Microbiol.54(3), 731–741 (2004).
   Google Scholar
• Schoen C, Tettelin H, Parkhill J, Frosch M. Genome flexibility in Neisseria meningitidis. Vaccine27(Suppl. 2), B103–B111 (2009).
   PubMed Web of Science ®Google Scholar
• Zhou J, Spratt BG. Sequence diversity within the argF, fbp and recA genes of natural isolates of Neisseria meningitidis: interspecies recombination within the argF gene. Mol. Microbiol.6(15), 2135–2146 (1992).
   PubMed Web of Science ®Google Scholar
• Holmes EC, Urwin R, Maiden MC. The influence of recombination on the population structure and evolution of the human pathogen Neisseria meningitidis. Mol. Biol. Evol.16(6), 741–749 (1999).
   PubMed Web of Science ®Google Scholar
• Moxon ER, Rainey PB, Nowak MA, Lenski RE. Adaptive evolution of highly mutable loci in pathogenic bacteria. Curr. Biol.4(1), 24–33 (1994).
   PubMed Web of Science ®Google Scholar
• Hammerschmidt S, Hilse R, van Putten JP, Gerardy-Schahn R, Unkmeir A, Frosch M. Modulation of cell surface sialic acid expression in Neisseria meningitidis via a transposable genetic element. EMBO J.15(1), 192–198 (1996).
   PubMed Web of Science ®Google Scholar
• Sawaya R, Arhin FF, Moreau F, Coulton JW, Mills EL. Mutational analysis of the promoter region of the porA gene of Neisseria meningitidis. Gene233(1–2), 49–57 (1999).
   Google Scholar
• Snyder LA, Butcher SA, Saunders NJ. Comparative whole-genome analyses reveal over 100 putative phase-variable genes in the pathogenic Neisseria spp. Microbiology147(Pt 8), 2321–2332 (2001).
   PubMed Web of Science ®Google Scholar
• Metruccio MM, Pigozzi E, Roncarati D et al. A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog.5(12), e1000710 (2009).
   PubMed Web of Science ®Google Scholar
• van der Ende A, Hopman CT, Dankert J. Multiple mechanisms of phase variation of PorA in Neisseria meningitidis. Infect. Immun.68(12), 6685–6690 (2000).
   Google Scholar
• Carson SD, Stone B, Beucher M, Fu J, Sparling PF. Phase variation of the gonococcal siderophore receptor FetA. Mol. Microbiol.36(3), 585–593 (2000).
   Google Scholar
• Sarkari J, Pandit N, Moxon ER, Achtman M. Variable expression of the Opc outer membrane protein in Neisseria meningitidis is caused by size variation of a promoter containing poly-cytidine. Mol. Microbiol.13(2), 207–217 (1994).
   PubMed Web of Science ®Google Scholar
• Martin P, Makepeace K, Hill SA, Hood DW, Moxon ER. Microsatellite instability regulates transcription factor binding and gene expression. Proc. Natl Acad. Sci. USA102(10), 3800–3804 (2005).
   PubMed Web of Science ®Google Scholar
• Schielke S, Huebner C, Spatz C et al. Expression of the meningococcal adhesin NadA is controlled by a transcriptional regulator of the MarR family. Mol. Microbiol.72(4), 1054–1067 (2009).
   Google Scholar
• Fox KL, Srikhanta YN, Jennings MP. Phase variable type III restriction-modification systems of host-adapted bacterial pathogens. Mol. Microbiol.65(6), 1375–1379 (2007).
   PubMedGoogle Scholar
• Srikhanta YN, Fox KL, Jennings MP. The phasevarion: phase variation of type III DNA methyltransferases controls coordinated switching in multiple genes. Nat. Rev. Microbiol.8(3), 196–206 (2010).
   PubMed Web of Science ®Google Scholar
• Davila S, Wright VJ, Khor CC et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat. Genet.42, 772–776 (2010).
   PubMed Web of Science ®Google Scholar
• Caugant DA, Froholm LO, Bovre K et al. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc. Natl Acad. Sci. USA83(13), 4927–4931 (1986).
   PubMed Web of Science ®Google Scholar
• Vogel U, Frosch M. Mechanisms of neisserial serum resistance. Mol. Microbiol.32(6), 1133–1139 (1999).
   PubMed Web of Science ®Google Scholar
• Walport MJ. Complement. First of two parts. N. Engl. J. Med.344(14), 1058–1066 (2001).
   PubMed Web of Science ®Google Scholar
• Andersen J, Berthelsen L, Bech Jensen B, Lind I. Dynamics of the meningococcal carrier state and characteristics of the carrier strains: a longitudinal study within three cohorts of military recruits. Epidemiol. Infect.121(1), 85–94 (1998).
   PubMed Web of Science ®Google Scholar
• Blackwell CC, Weir DM, James VS et al. Secretor status, smoking and carriage of Neisseria meningitidis. Epidemiol. Infect.104(2), 203–209 (1990).
   PubMed Web of Science ®Google Scholar
• Kriz P, Bobak M, Kriz B. Parental smoking, socioeconomic factors, and risk of invasive meningococcal disease in children: a population based case–control study. Arch. Dis. Child.83(2), 117–121 (2000).
   PubMed Web of Science ®Google Scholar
• Nassif X, So M. Interaction of pathogenic neisseriae with nonphagocytic cells. Clin. Microbiol. Rev.8(3), 376–388 (1995).
   Google Scholar
• Johansson L, Rytkonen A, Bergman P et al. CD46 in meningococcal disease. Science301(5631), 373–375 (2003).
   PubMed Web of Science ®Google Scholar
• Tinsley CR, Heckels JE. Variation in the expression of pili and outer membrane protein by Neisseria meningitidis during the course of meningococcal infection. J. Gen. Microbiol.132(9), 2483–2490 (1986).
   PubMedGoogle Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med.129(6), 1327–1348 (1969).
   PubMed Web of Science ®Google Scholar
• Sjolinder H, Jonsson AB. Imaging of disease dynamics during meningococcal sepsis. PLoS One2(2), e241 (2007).
   PubMedGoogle Scholar
• Dehio C, Gray-Owen SD, Meyer TF. The role of neisserial Opa proteins in interactions with host cells. Trends Microbiol.6(12), 489–495 (1998).
   PubMed Web of Science ®Google Scholar
• Deghmane AE, Petit S, Topilko A et al. Intimate adhesion of Neisseria meningitidis to human epithelial cells is under the control of the crgA gene, a novel LysR-type transcriptional regulator. EMBO J.19(5), 1068–1078 (2000).
   Google Scholar
• Taha MK, Morand PC, Pereira Y et al. Pilus-mediated adhesion of Neisseria meningitidis: the essential role of cell contact-dependent transcriptional upregulation of the PilC1 protein. Mol. Microbiol.28(6), 1153–1163 (1998).
   Google Scholar
• de Vries FP, Cole R, Dankert J, Frosch M, van Putten JP. Neisseria meningitidis producing the Opc adhesin binds epithelial cell proteoglycan receptors. Mol. Microbiol.27(6), 1203–1212 (1998).
   PubMedGoogle Scholar
• Porat N, Apicella MA, Blake MS. A lipooligosaccharide-binding site on HepG2 cells similar to the gonococcal opacity-associated surface protein Opa. Infect. Immun.63(6), 2164–2172 (1995).
   Google Scholar
• Grifantini R, Bartolini E, Muzzi A et al. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat. Biotechnol.20(9), 914–921 (2002).
   PubMed Web of Science ®Google Scholar
• Williams JN, Skipp PJ, O’Connor CD, Christodoulides M, Heckels JE. Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates. Infect. Immun.77(11), 5080–5089 (2009).
   PubMed Web of Science ®Google Scholar
• de Filippis I. Quest for a broad-range vaccine against Neisseria meningitidis serogroup B: implications of genetic variations of the surface-exposed proteins. J. Med. Microbiol.58(Pt 9), 1127–1132 (2009).
   Google Scholar
• Halperin SA, Langley JM, Smith B et al. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine25(3), 450–457 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobsson S, Hedberg ST, Molling P et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine27(10), 1579–1584 (2009).
   PubMed Web of Science ®Google Scholar
• West D, Reddin K, Matheson M et al. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect. Immun.69(3), 1561–1567 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrari G, Garaguso I, Adu-Bobie J et al. Outer membrane vesicles from group B Neisseria meningitidis Δgna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics6(6), 1856–1866 (2006).
   PubMed Web of Science ®Google Scholar
• Snyder LA, Saunders NJ. The majority of genes in the pathogenic Neisseria species are present in non-pathogenic Neisseria lactamica, including those designated as ‘virulence genes’. BMC Genomics7, 129 (2006).
   Google Scholar
• Suker J, Feavers IM, Maiden MC. Monoclonal antibody recognition of members of the meningococcal P1.10 variable region family: implications for serological typing and vaccine design. Microbiology142(Pt 1), 63–69 (1996).
   Google Scholar
• McGuinness BT, Clarke IN, Lambden PR et al. Point mutation in meningococcal porA gene associated with increased endemic disease. Lancet337(8740), 514–517 (1991).
   PubMed Web of Science ®Google Scholar
• van der Ende A, Hopman CT, Dankert J. Deletion of porA by recombination between clusters of repetitive extragenic palindromic sequences in Neisseria meningitidis. Infect. Immun.67(6), 2928–2934 (1999).
   Google Scholar
• van der Ende A, Hopman CT, Zaat S, Essink BB, Berkhout B, Dankert J. Variable expression of class 1 outer membrane protein in Neisseria meningitidis is caused by variation in the spacing between the -10 and -35 regions of the promoter. J. Bacteriol.177(9), 2475–2480 (1995).
   Google Scholar
• Arhin FF, Moreau F, Coulton JW, Mills EL. Sequencing of porA from clinical isolates of Neisseria meningitidis defines a subtyping scheme and its genetic regulation. Can. J. Microbiol.44(1), 56–63 (1998).
   Google Scholar
• Cartwright K, Morris R, Rumke H et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine17(20–21), 2612–2619 (1999).
   PubMed Web of Science ®Google Scholar
• de Kleijn ED, de Groot R, Labadie J et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age. Vaccine18(15), 1456–1466 (2000).
   PubMed Web of Science ®Google Scholar
• Martin SL, Borrow R, van der Ley P, Dawson M, Fox AJ, Cartwright KA. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine18(23), 2476–2481 (2000).
   PubMed Web of Science ®Google Scholar
• van der Ley P, Heckels JE, Virji M, Hoogerhout P, Poolman JT. Topology of outer membrane porins in pathogenic Neisseria spp. Infect. Immun.59(9), 2963–2971 (1991).
   PubMed Web of Science ®Google Scholar
• Zapata GA, Vann WF, Rubinstein Y, Frasch CE. Identification of variable region differences in Neisseria meningitidis class 3 protein sequences among five group B serotypes. Mol. Microbiol.6(23), 3493–3499 (1992).
   Google Scholar
• Sacchi CT, Lemos AP, Whitney AM et al. Correlation between serological and sequencing analyses of the PorB outer membrane protein in the Neisseria meningitidis serotyping system. Clin. Diagn. Lab. Immunol.5(3), 348–354 (1998).
   PubMedGoogle Scholar
• Maiden MC. Population genetics of a transformable bacterium: the influence of horizontal genetic exchange on the biology of Neisseria meningitidis. FEMS Microbiol. Lett.112(3), 243–250 (1993).
   Google Scholar
• Dyet KH, Martin DR. Clonal analysis of the serogroup B meningococci causing New Zealand’s epidemic. Epidemiol. Infect.134(2), 377–383 (2006).
   PubMed Web of Science ®Google Scholar
• Dyet KH, Martin DR. Sequence variation in the porB gene from B:P1.4 meningococci causing New Zealand’s epidemic. J. Clin. Microbiol.43(2), 838–842 (2005).
   Google Scholar
• Rosenqvist E, Hoiby EA, Wedege E, Kusecek B, Achtman M. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J. Infect. Dis.167(5), 1065–1073 (1993).
   PubMed Web of Science ®Google Scholar
• Jolley KA, Appleby L, Wright JC, Christodoulides M, Heckels JE. Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci. Infect. Immun.69(6), 3809–3816 (2001).
   PubMed Web of Science ®Google Scholar
• Tinsley CR, Virji M, Heckels JE. Antibodies recognizing a variety of different structural motifs on meningococcal Lip antigen fail to demonstrate bactericidal activity. J. Gen. Microbiol.138(11), 2321–2328 (1992).
   Google Scholar
• Munkley A, Tinsley CR, Virji M, Heckels JE. Blocking of bactericidal killing of Neisseria meningitidis by antibodies directed against class 4 outer membrane protein. Microb. Pathog.11(6), 447–452 (1991).
   Google Scholar
• Lissolo L, Maitre-Wilmotte G, Dumas P, Mignon M, Danve B, Quentin-Millet MJ. Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infect. Immun.63(3), 884–890 (1995).
   PubMed Web of Science ®Google Scholar
• Danve B, Lissolo L, Mignon M et al. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine11(12), 1214–1220 (1993).
   PubMed Web of Science ®Google Scholar
• Ala’Aldeen DA, Borriello SP. The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains. Vaccine14(1), 49–53 (1996).
   PubMed Web of Science ®Google Scholar
• Heckels JE. Structure and function of pili of pathogenic Neisseria species. Clin. Microbiol. Rev.2(Suppl.), S66–S73 (1989).
   Web of Science ®Google Scholar
• Cehovin A, Winterbotham M, Lucidarme J et al. Sequence conservation of pilus subunits in Neisseria meningitidis. Vaccine28(30), 4817–4826 (2010).
   Google Scholar
• Cehovin A, Pelicic V. Minor pilins as novel vaccine candidates against Neisseria meningitidis. Presented at: Meningitis Research Foundation’s 2009 Conference – Meningitis and Septicemia in Children and Adults. The Royal Society of Medicine, London, UK, 11–12 November 2009.
   Google Scholar
• Mandrell RE, Griffiss JM, Macher BA. Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens. Carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize crossreacting antigens on LOS and human erythrocytes. J. Exp. Med.168(1), 107–126 (1988).
   PubMedGoogle Scholar
• Drabick JJ, Brandt BL, Moran EE, Saunders NB, Shoemaker DR, Zollinger WD. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine18(1–2), 160–172 (1999).
   PubMedGoogle Scholar
• Zollinger WD, Moran EE, Devi SJ, Frasch CE. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect. Immun.65(3), 1053–1060 (1997).
   PubMed Web of Science ®Google Scholar
• Estabrook MM, Jarvis GA, McLeod Griffiss J. Affinity-purified human immunoglobulin G that binds a lacto-N-neotetraose-dependent lipooligosaccharide structure is bactericidal for serogroup B Neisseria meningitidis. Infect. Immun.75(2), 1025–1033 (2007).
   Google Scholar
• Weynants V, Denoel P, Devos N et al. Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect. Immun.. 77(5), 2084–2093 (2009).
   PubMed Web of Science ®Google Scholar
• Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden MC. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect. Immun.72(10), 5955–5962 (2004).
   PubMed Web of Science ®Google Scholar
• Feavers IM, Pizza M. Meningococcal protein antigens and vaccines. Vaccine27(Suppl. 2), B42–B50 (2009).
   PubMedGoogle Scholar
• Gupta S, Maiden MC. Exploring the evolution of diversity in pathogen populations. Trends Microbiol.9(4), 181–185 (2001).
   PubMed Web of Science ®Google Scholar
• Achtman M, van der Ende A, Zhu P et al. Molecular epidemiology of serogroup A meningitis in Moscow, 1969 to 1997. Emerg. Infect. Dis.7(3), 420–427 (2001).
   PubMed Web of Science ®Google Scholar
• van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine25(13), 2491–2496 (2007).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol. Rev.31(1), 101–107 (2007).
   PubMed Web of Science ®Google Scholar
• Claassen I, Meylis J, van der Ley P et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine14(10), 1001–1008 (1996).
   PubMed Web of Science ®Google Scholar
• Weynants VE, Feron CM, Goraj KK et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect. Immun.75(11), 5434–5442 (2007).
   PubMed Web of Science ®Google Scholar
• Zollinger WD, Donets MA, Schmiel DH et al. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine28(31), 5057–5067 (2010).
   PubMed Web of Science ®Google Scholar
• Oliver KJ, Reddin KM, Bracegirdle P et al. Neisseria lactamica protects against experimental meningococcal infection. Infect. Immun.70(7), 3621–3626 (2002).
   PubMed Web of Science ®Google Scholar
• Sardinas G, Reddin K, Pajon R, Gorringe A. Outer membrane vesicles of Neisseria lactamica as a potential mucosal adjuvant. Vaccine24(2), 206–214 (2006).
   PubMed Web of Science ®Google Scholar
• Gorringe AR, Taylor S, Brookes C et al. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin. Vaccine Immunol.16(8), 1113–1120 (2009).
   PubMedGoogle Scholar
• Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J. Med. Microbiol.53(Pt 9), 821–832 (2004).
   PubMed Web of Science ®Google Scholar
• Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet359(9320), 1829–1831 (2002).
   PubMed Web of Science ®Google Scholar
• Rosenqvist E, Bjune G, Feiring B et al. Changes in carrier status of Neisseria meningitidis in teenagers during a group B outer membrane vaccination trial in Norway. In: Proceedings of the 8th International Pathogenic Neisseria Conference. Conde-Glez CJ, Morse S, Rice P, Sparling F, Calderon E (Eds). Instituto Nacional de Salud Publica-Morelos-Mexico, Mexico, 895–901 (1994).
   Google Scholar
• Comanducci M, Bambini S, Brunelli B et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med.195(11), 1445–1454 (2002).
   PubMed Web of Science ®Google Scholar
• Comanducci M, Bambini S, Caugant DA et al. NadA diversity and carriage in Neisseria meningitidis. Infect. Immun.72(7), 4217–4223 (2004).
   PubMed Web of Science ®Google Scholar
• Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine27(21), 2794–2803 (2009).
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD et al. Serum bactericidal antibody against an extended panel of meningococcal strains following immunisation with novel serogroup B meningococcal vaccines in infancy. Clin. Infect. Dis. (In Press) (2010).
   Google Scholar
• Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J. Infect. Dis.195(10), 1472–1479 (2007).
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Biolchi A, Serruto D et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine28(31), 5023–5030 (2010).
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science287(5459), 1816–1820 (2000).
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Comanducci M, Findlow J et al. Characterisation of fHbp, nhba (gna2132), nadA, porA and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008, and potential coverage of an investigational group B meningococcal vaccine. Clin. Vaccine Immunol.17(6), 919–929 (2010).
   PubMed Web of Science ®Google Scholar
• Serruto D, Spadafina T, Ciucchi L et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc. Natl Acad. Sci. USA107(8), 3770–3775 (2010).
   PubMed Web of Science ®Google Scholar
• Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis.188(11), 1730–1740 (2003).
   PubMed Web of Science ®Google Scholar
• Plested JS, Granoff DM. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin. Vaccine Immunol.15(5), 799–804 (2008).
   Google Scholar
• Masignani V, Comanducci M, Giuliani MM et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med.197(6), 789–799 (2003).
   PubMed Web of Science ®Google Scholar
• Madico G, Welsch JA, Lewis LA et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol.177(1), 501–510 (2006).
   PubMed Web of Science ®Google Scholar
• Schneider MC, Exley RM, Chan H et al. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol.176(12), 7566–7575 (2006).
   PubMed Web of Science ®Google Scholar
• Schneider MC, Prosser BE, Caesar JJ et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature458(7240), 890–893 (2009).
   PubMed Web of Science ®Google Scholar
• Mascioni A, Bentley BE, Camarda R et al. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J. Biol. Chem.284(13), 8738–8746 (2009).
   PubMed Web of Science ®Google Scholar
• Beernink PT, Leipus A, Granoff DM. Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin. Vaccine Immunol.13(7), 758–763 (2006).
   PubMedGoogle Scholar
• Murphy E, Andrew L, Lee KL et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis.200(3), 379–389 (2009).
   PubMed Web of Science ®Google Scholar
• Beernink PT, Granoff DM. The modular architecture of meningococcal factor H-binding protein. Microbiology155(Pt 9), 2873–2883 (2009).
   PubMedGoogle Scholar
• Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine28(9), 2122–2129 (2010).
   PubMed Web of Science ®Google Scholar
• Bigwood R, Feavers I, Chan H, Vipond C. Exploring the expression levels of recombinant antigens and the murine response to Novartis recombinant MenB investigational vaccine. Presented at: Meningitis Research Foundation’s Conference. London, UK, 11–12 November 2009.
   Google Scholar
• Snape MD, Dawson T, Oster P et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life. A randomized comparative trial. Pediatr. Infect. Dis. J. (In Press) (2010).
   Google Scholar
• Jiang HQ, Hoiseth SK, Harris SL et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine28(37), 6086–6093(2010).
   PubMed Web of Science ®Google Scholar
• Richmond P, Marshall HS, Nissen MD et al. A randomized, observed-blinded, active control, Phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescent aged 8 to 14 years. Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7–12 September 2008.
   Google Scholar
• Beernink PT, Shaughnessy J, Ram S, Granoff DM. Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor H binding. Clin. Vaccine Immunol.17(7), 1074–1078 (2010).
   Google Scholar
• Lewis LA, Ngampasutadol J, Wallace R, Reid JEA, Vogel U, Ram S. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog.6(7), e1001027 (2010).
   PubMed Web of Science ®Google Scholar
• Cummings CA, Relman DA. Using DNA microarrays to study host–microbe interactions. Emerg. Infect. Dis.6(5), 513–525 (2000).
   PubMed Web of Science ®Google Scholar
• Schoolnik GK. Microarray analysis of bacterial pathogenicity. Adv. Microb. Physiol.46, 1–45 (2002).
   PubMed Web of Science ®Google Scholar
• Kurz S, Hubner C, Aepinus C et al. Transcriptome-based antigen identification for Neisseria meningitidis. Vaccine21(7–8), 768–775 (2003).
   PubMed Web of Science ®Google Scholar
• Bernardini G, Braconi D, Santucci A. The analysis of Neisseria meningitidis proteomes: reference maps and their applications. Proteomics7(16), 2933–2946 (2007).
   PubMed Web of Science ®Google Scholar
• Mignogna G, Giorgi A, Stefanelli P et al. Inventory of the proteins in Neisseria meningitidis serogroup B strain MC58. J. Proteome Res.4(4), 1361–1370 (2005).
   PubMedGoogle Scholar
• Uli L, Castellanos-Serra L, Betancourt L et al. Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Proteomics6(11), 3389–3399 (2006).
   PubMed Web of Science ®Google Scholar
• Vipond C, Suker J, Jones C, Tang C, Feavers IM, Wheeler JX. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ 98/254. Proteomics6(11), 3400–3413 (2006).
   PubMed Web of Science ®Google Scholar
• Sanchez S, Abel A, Arenas J, Criado MT, Ferreiros CM. Cross-linking analysis of antigenic outer membrane protein complexes of Neisseria meningitidis. Res. Microbiol.157(2), 136–142 (2006).
   PubMed Web of Science ®Google Scholar
• Serruto D, Rappuoli R. Post-genomic vaccine development. FEBS Lett.580(12), 2985–2992 (2006).
   PubMed Web of Science ®Google Scholar
• Ronning DR, Klabunde T, Besra GS, Vissa VD, Belisle JT, Sacchettini JC. Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. Nat. Struct. Biol.7(2), 141–146 (2000).
   PubMedGoogle Scholar
• Cantini F, Savino S, Scarselli M et al. Solution structure of the immunodominant domain of protective antigen GNA1870 of Neisseria meningitidis. J. Biol. Chem.281(11), 7220–7227 (2006).
   PubMed Web of Science ®Google Scholar
• Cantini F, Veggi D, Dragonetti S et al. Solution structure of the factor H-binding protein, a survival factor and protective antigen of Neisseria meningitidis. J. Biol. Chem.284(14), 9022–9026 (2009).
   PubMedGoogle Scholar
• Mora M, Donati C, Medini D, Covacci A, Rappuoli R. Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach. Curr. Opin Microbiol.9(5), 532–536 (2006).
   PubMed Web of Science ®Google Scholar
• Grifantini R, Bartolini E, Muzzi A et al. Gene expression profile in Neisseria meningitidis and Neisseria lactamica upon host-cell contact: from basic research to vaccine development. Ann NY Acad. Sci.975, 202–216 (2002).
   PubMed Web of Science ®Google Scholar
• Sun YH, Bakshi S, Chalmers R, Tang CM. Functional genomics of Neisseria meningitidis pathogenesis. Nat. Med.6(11), 1269–1273 (2000).
   PubMed Web of Science ®Google Scholar
• Perrin A, Bonacorsi S, Carbonnelle E et al. Comparative genomics identifies the genetic islands that distinguish Neisseria meningitidis, the agent of cerebrospinal meningitis, from other Neisseria species. Infect. Immun.70(12), 7063–7072 (2002).
   PubMed Web of Science ®Google Scholar
• Heckels JE, Williams JN. The influence of genomics and proteomics on the development of potential vaccines against meningococcal infection. Genome Med.2(7), 43 (2010).
   Google Scholar